Comparative Pharmacology
Head-to-head clinical analysis: DEPAKOTE versus LEVETIRACETAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPAKOTE versus LEVETIRACETAM.
DEPAKOTE vs LEVETIRACETAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases GABA levels by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase; also blocks voltage-gated sodium channels and T-type calcium channels.
Levetiracetam's precise mechanism of action is unknown. It binds to synaptic vesicle protein 2A (SV2A), which may modulate neurotransmitter release and reduce neuronal excitability. It also inhibits N-type calcium channels and reduces calcium influx, contributing to antiepileptic effects.
Initial dose 750 mg/day PO in divided doses; increase by 250-500 mg/day every 3-7 days; maintenance dose 1000-2000 mg/day PO divided BID or TID; maximum 60 mg/kg/day.
500-1500 mg PO/IV BID; initial 500 mg BID, titrate by 500 mg BID every 2 weeks as tolerated; maximum 3000 mg/day.
None Documented
None Documented
Clinical Note
moderateLevetiracetam + Venlafaxine
"The risk or severity of adverse effects can be increased when Levetiracetam is combined with Venlafaxine."
Clinical Note
moderateLevetiracetam + Nefazodone
"The risk or severity of adverse effects can be increased when Levetiracetam is combined with Nefazodone."
Clinical Note
moderateLevetiracetam + Ranolazine
"The serum concentration of Ranolazine can be increased when it is combined with Levetiracetam."
Clinical Note
moderateLevetiracetam + Stiripentol
Terminal: 9-16 hours (mean 12 h); extended with hepatic dysfunction, co-administered enzyme inhibitors, or in elderly.
6–8 hours in adults; prolonged to 10–11 hours in mild-to-moderate renal impairment (CrCl 30–50 mL/min) and 16–24 hours in severe impairment (CrCl <30 mL/min); neonates up to 16 hours.
Renal: <3% as unchanged drug; >95% as metabolites (glucuronide conjugates, oxidation products). Biliary/fecal: minor, <5%.
Primarily renal (66% unchanged, 27% as inactive metabolite); minimal fecal (<2%).
Category C
Category A/B
Anticonvulsant
Anticonvulsant
"The risk or severity of adverse effects can be increased when Levetiracetam is combined with Stiripentol."